Clinical Trial Results:
A randomised, double-blind, four way cross-over, placebo controlled trial to evaluate the clinical efficacy, onset of action and drug activity at 22-26 hours following the drug intake of Bilastne 20 mg vs placebo and in competition to Cetirizine 10 mg, Fexofenadine 120 mg in reducing symptoms of seasonal allergic rhinitis in grass pollen sensitized volunteers exposed on 2 consecutive days in the Vienna Challenge Chamber
Summary
|
|
EudraCT number |
2006-003004-19 |
Trial protocol |
AT |
Global completion date |
21 Dec 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Jun 2022
|
First version publication date |
25 Jun 2022
|
Other versions |
|
Summary report(s) |
CSR Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.